Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

337

Participants

Timeline

Start Date

July 21, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

August 14, 2018

Conditions
Malaria
Interventions
BIOLOGICAL

PfSPZ Vaccine

Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites

OTHER

Normal Saline

0.9% Sodium chloride

Trial Locations (1)

Unknown

Center for Global Health Research, KEMRI, Kisian

Sponsors
All Listed Sponsors
collaborator

Kenya Medical Research Institute

OTHER

collaborator

Centers for Disease Control and Prevention

FED

collaborator

National Institutes of Health (NIH)

NIH

collaborator

University of Maryland

OTHER

lead

Sanaria Inc.

INDUSTRY